EXPONENT, INC.
In the published model solve dated 2026-Q2, anchored at $71.53, EXPONENT, INC. (EXPO) is priced for +23.1% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed July 26, 2026 from SEC EDGAR filings.
• Revenue rose 4.2% to 582.0 million dollars in fiscal 2025 while billable hours fell 2% to 1,468,000 and utilisation held at 73%, so the growth came from billing rates rather than from doing more work [Source: Exponent fiscal 2025 annual report]. • Momentum turned in the March 2026 quarter: revenues before reimbursements rose 10.5% and pre-tax income 12.1%, with diluted earnings of 59 cents against 52 cents a year earlier [Source: Exponent first-quarter 2026 report]. • The next dated event is
Is EXPO overvalued? See what's priced in →
348 institutional managers reported holding EXPO in 13F filings for the quarter ended 2026-03-31. Together they hold about 95% of the company; the top 10 hold 52%. 47 opened new positions that quarter. Held by BlackRock, Vanguard Group, State Street, among others. On the short side, 2.7M shares were sold short as of the 2026-06-15 count, about 5% of shares outstanding (4.5 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
EXPO has cut its share count 5.4% over the past five years, spending $362.34M on repurchases. It pays a dividend, and has for 13 years running; the current rate is $1.20 a share annually. Cash returned over the past three years: $162.66M in dividends and $206.49M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at EXPO over the trailing three years. Absence is a fact about the company, not a signal. 13 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
EXPO's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-08 | -6.3% | +3.7% |
| 2023-11-04 | -12.3% | +15.1% |
| 2024-02-24 | +1.0% | +21.1% |
| 2024-05-04 | +18.3% | -0.1% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
EXPO's latest 8-K filings: 2026-07-30 (items 2.02, 7.01, 9.01); 2026-06-10 (items 5.07); 2026-04-30 (items 2.02, 7.01, 9.01); 2026-04-06 (items 5.02, 9.01); 2026-02-05 (items 2.02, 7.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 26, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.